Retatrutide
Triple-pathway fat loss.
30-day full guarantee. Notice a difference or it's free — no return required.
What it does
Mechanism
GLP-1 pathway
Slows gastric emptying and acts on hypothalamic satiety centres — you eat less without forcing it.
GIP pathway
Amplifies the insulin response and enhances fat metabolism in adipose tissue.
Glucagon pathway
Increases energy expenditure and liver fat oxidation — the piece that separates Retatrutide from dual agonists.
The Evidence
These findings describe peer-reviewed research on Retatrutide — the active(s) in Peak Burn. Claims are about the compound, not our formulation.
Jastreboff et al. · NEJM 2023 · Phase 2 Obesity Trial
"Retatrutide produced a 24.2% mean reduction in body weight at 48 weeks." At the top dose, 83% of participants lost at least 15% of body weight.
The largest weight-loss result published for any obesity pharmacotherapy at the time. PMID 37366315.
Triple-agonist mechanism · Eur J Med Chem 2026
Confirms simultaneous GLP-1 / GIP / glucagon receptor agonism as the class mechanism.
Retatrutide remains in Phase 3 development (TRIUMPH); not yet approved — supplied for research use.
Retatrutide has human Phase 2 RCT evidence — the strongest in our range.
The Product
Your Peak Burn pen, a 30-day supply of single-use needle tips, and bacteriostatic water for reconstitution — one discreet, unbranded box.
Questions
Ships as lyophilised powder in a sterile pen. Reconstitute once with the bacteriostatic water supplied, then administer a quick subcutaneous injection. Ships stable at ambient temperature; refrigerate on arrival.
Supplied for research and educational purposes. Not TGA-approved for therapeutic use and not sold as a medicine. Australian adults 18+ only.
Standard workplace and roadside screens test for recreational substances — peptides don't appear on them. If you compete under WADA rules, check the current prohibited list before use.
30-day full refund if you don't notice a difference. No return required.
